Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
F 6.17 -1.28% -0.08
ADVM closed down 1.28 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Down 3% about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 21 hours ago
New 52 Week Low about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adverum Biotechnologies, Inc. Description

Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Gene Therapy Macular Degeneration Genetic Diseases Retina Wet Age Related Macular Degeneration Rare Genetic Disease Gene Therapy Products Regeneron Adverum Biotechnologies Gene Therapy Of The Human Retina

Is ADVM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.7
52 Week Low 6.0
Average Volume 209,402
200-Day Moving Average 10.00
50-Day Moving Average 7.45
20-Day Moving Average 7.50
10-Day Moving Average 7.25
Average True Range 0.45
RSI (14) 28.06
ADX 16.12
+DI 18.09
-DI 31.26
Chandelier Exit (Long, 3 ATRs) 6.97
Chandelier Exit (Short, 3 ATRs) 7.36
Upper Bollinger Bands 8.61
Lower Bollinger Band 6.40
Percent B (%b) -0.1
BandWidth 29.47
MACD Line -0.27
MACD Signal Line -0.07
MACD Histogram -0.1973
Fundamentals Value
Market Cap 623.34 Million
Num Shares 101 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -4.90
Price-to-Sales 62.39
Price-to-Book 1.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.68
Resistance 3 (R3) 6.68 6.51 6.60
Resistance 2 (R2) 6.51 6.38 6.51 6.57
Resistance 1 (R1) 6.34 6.30 6.26 6.34 6.54
Pivot Point 6.17 6.17 6.13 6.17 6.17
Support 1 (S1) 6.00 6.04 5.92 6.00 5.80
Support 2 (S2) 5.83 5.96 5.83 5.77
Support 3 (S3) 5.66 5.83 5.75
Support 4 (S4) 5.66